Tanja De Gruijl

Tanja de Gruijl heads the Immunotherapy and Immune-monitoring Lab at the VU University medical center-Cancer Center in Amsterdam, where she has been appointed Professor of Translational Tumor Immunology and holds a Fenna Diemer Lindeboom Chair. She has over 20 years of experience in the field of tumor immunology with over 150 peer-reviewed publications to her name. Her research ranges from preclinical topics to immune-monitoring of Phase I-III clinical trials. Her main line of research is the in vivo targeting and modulation of dendritic cells (DC). Further topics of research include tumor-mediated immune suppression, control of DC differentiation, the effects of cytostatic drugs on DC development and functionality, and the immune potentiation of tumor-draining lymph nodes and the tumor microenvironment. Her research has been supported by fellowships and grants from the Netherlands Organization for Scientific Research (NWO) and the Royal Dutch Cancer Society (KWF) and she is a recipient of a competitive research award of the Prostate Cancer Foundation. She is a member of the Grant Review committee of the Melanoma Research Alliance, a member of the scientific council of the Dutch Cancer Society (KWF), Associate Editor of Cancer Immunology Research, and currently chairs the Dutch Tumor Immunology Working Party.